A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis

Trial Profile

A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Sparsentan (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Sponsors Retrophin
  • Most Recent Events

    • 17 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top